اوسلتامیویر
لینک دانلود PDF
http://www.drjadid.com/wp-content/uploads/2020/03/تجویز-و-تعدیل-دوز-اوسلتامی-ویر-برای-پزشکان.pdf
Oseltamivir(Tamiflu) Dosing & Uses
ADULTPEDIATRIC
Dosage Forms & Strengths
capsule
- ۳۰mg
- ۴۵mg
- ۷۵mg
powder for oral suspension
- ۶mg/mL
MORE…
Influenza A and B Prophylaxis
۷۵ mg PO qDay for at least 10 days
Dosing considerations
- Initiate within 48 hours of exposure
- For community outbreak, may administer for up to 6 weeks
Influenza A and B Treatment
۷۵ mg PO q12hr for 5 days
Dosing considerations
- Initiate within 48 hours of influenza symptom onset
H1N1 Influenza A (Swine Flu) Prophylaxis (Off-label)
۷۵ mg PO qDay
Dosing considerations
- Postexposure prophylaxis: Initiate within 7 days of exposure and continue for at least 10 days
- Preexposure prophylaxis (community outbreak): Initiate during potential exposure period and continue for 10 days after last known exposure
- Consider longer duration (>5 days) in severely ill patients who remain severely ill after 5 days of therapy
H1N1 Influenza A (Swine Flu) Treatment (Off-label)
۷۵ mg PO q12hr for 5 days
Dosing considerations
- Initiate within 48 hours of influenza symptom onset
Dosage Modifications
Renal impairment
- Treatment
- CrCl >60 to 90 mL/min: No dosage adjustment necessary
- CrCl >30 to 60 mL/min: 30 mg PO BID
- CrCl >10 to 30 mL/min: 30 mg PO qDay
- End-stage renal disease (ESRD), not undergoing dialysis: Not recommended (not studied)
- ESRD CrCl ≤۱۰ mL/min; on hemodialysis: 30 mg PO immediately and then 30 mg after every hemodialysis cycle; treatment duration not to exceed 5 days
- ESRD CrCl ≤۱۰ mL/min; on CAPD: Single dose of 30 mg administered immediately
- Prophylaxis
- CrCl >60 mL/min: No dose adjustment necessary
- CrCl >30 to 60 mL/min: 30 mg PO qDay
- CrCl >10 to 30 mL/min: 30 mg PO every other day
- End-stage renal disease (ESRD), not undergoing dialysis: Not recommended (not studied)
- ESRD CrCl ≤۱۰ mL/min; on hemodialysis: 30 mg PO immediately and then 30 mg after alternate hemodialysis cycle
- ESRD CrCl ≤۱۰ mL/min; on CAPD: 30 mg immediately and then 30 mg once weekly
Hepatic impairment
- Mild-to-moderate: No doage adjustment necessary
- Severe: Not studied
Interactions
Enter a drug nameand oseltamivir
All InteractionsSort By: Severity Name
Contraindicated (0)
Serious – Use Alternative (1)
- pretomanid
Monitor Closely (8)
- clopidogrel
- influenza virus vaccine quadrivalent
- influenza virus vaccine quadrivalent, intranasal
- influenza virus vaccine quadrivalent, recombinant
- influenza virus vaccine trivalent
- influenza virus vaccine trivalent, adjuvanted
- influenza virus vaccine trivalent, recombinant
- probenecid
Minor (0)
Adverse Effects
۱-۱۰%
Abdominal pain
Conjunctivitis
Ear disorder
Epistaxis
Insomnia
Nausea
Vomiting
Vertigo
<1%
Aggravation of diabetes
Anemia
Arrhythmia
Confusion
Delirium
Hemorrhagic colitis
Hepatitis
Humerus fracture
Peritonsillar abscess
Pneumonia
Pseudomembranous colitis
Pyrexia
Rash
Seizure
Transaminases increased
Toxic epidermal necrolysis
Unstable angina
Swelling of face or tongue
Postmarketing Reports
Hypothermia
Diaper rash (2 weeks to <1 year of age)
Dermatitis
Urticaria
Eczema
Stevens-Johnson Syndrome
Erythema multiforme
Gastrointestinal bleeding
Abnormal liver function tests
Pregnancy & Lactation
Pregnancy
There are no adequate and well–controlled studies in pregnant women to inform a drug–associated risk of adverse developmental outcomes; available published epidemiological data suggest that the drug, taken in any trimester, is not associated with an increased risk of birth defects; however, these studies individually are limited by small sample sizes, use of different comparison groups, and some lacked information on dose, which preclude a definitive assessment of the risk
Pregnant women are at higher risk of severe complications from influenza, which may lead to adverse pregnancy and/or fetal outcomes including maternal death, still births, birth defects, preterm delivery, low birth weight and small for gestational age
Animal data
- In animal reproduction studies, no adverse developmental effects were observed at clinically relevant exposures
Lactation
Based on limited published data, have shown the drug to be present in human milk at low levels considered unlikely to lead to toxicity in the breastfed infant; postmarketing experience has not reported any information to suggest serious adverse effects to drug exposure via breast milk in infants; it is not known if drug affects human milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
